Allogene Therapeutics Inc... (ALLO)

NASDAQ: ALLO · Real-Time Price · USD

1.70

0.02 (1.19%)

At close: May 01, 2025, 3:59 PM

1.70

0.00%

Pre-market: May 02, 2025, 09:21 AM EDT

Allogene Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Revenue	22K	95K	243K	38.49M	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	242.91M	16.73M	13.06M	11.54M	5.03M	1.5M	n/a
Gross Profit	22K	-242.82M	-16.48M	25.42M	-11.54M	-5.03M	-1.5M	n/a
Operating Income	-273.2M	-327.74M	-335.45M	-255.79M	-258.24M	-202.01M	-192.84M	-2K
Interest Income	20.15M	18.31M	4.57M	1.71M	9.16M	17.35M	5.79M	n/a
Pretax Income	-257.15M	-327.26M	-332.63M	-257M	-250.22M	-184.93M	-211.62M	-2K
Net Income	-257.59M	-327.26M	-329.81M	-244.84M	-233.47M	-184.59M	-211.5M	-2K
Selling & General & Admin	65.2M	71.67M	79.31M	74.11M	65.26M	57.47M	40.98M	2K
Research & Development	192.3M	242.91M	256.39M	220.18M	192.99M	144.53M	151.86M	n/a
Other Expenses	15.72M	13.24M	-1.75M	-2.93M	-1.14M	-268K	-21.21M	n/a
Operating Expenses	273.22M	327.83M	335.69M	294.28M	258.24M	202.01M	192.84M	2K
Interest Expense	181K	n/a	n/a	n/a	n/a	n/a	3.36M	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-22K
Cost & Expenses	273.22M	327.83M	335.69M	294.28M	258.24M	202.01M	192.84M	2K
Income Tax Expense	443K	n/a	-2.82M	-12.17M	-16.75M	-331K	-117K	-24K
Shares Outstanding (Basic)	194.81M	156.93M	143.15M	135.82M	120.37M	101.06M	28.95M	117.93M
Shares Outstanding (Diluted)	194.81M	156.93M	143.15M	135.82M	120.37M	101.06M	28.95M	117.93M
EPS (Basic)	-1.32	-2.09	-2.3	-1.8	-1.94	-1.83	-7.31	n/a
EPS (Diluted)	-1.32	-2.09	-2.3	-1.8	-1.94	-1.83	-7.31	n/a
EBITDA	-243.33M	-300.29M	-321.24M	-169.74M	-250.81M	-179.9M	-206.76M	22K
EBIT	-256.97M	-314.49M	-335.54M	-180.19M	-250.22M	-184.93M	-208.26M	-2K
Depreciation & Amortization	13.64M	14.2M	14.29M	10.45M	11.54M	5.03M	1.5M	24K